Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-Targeted CAR-T in Advanced Lung Cancer
NCT06903117Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of C-13-60 in lung cancer (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoint: Safety and tolerability of CAR T cell preparations at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
C-13-60
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06903117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903117.